Ligand-mediated gene induction by steroid receptors is a multistep process characterized by a dose-response curve for gene product that follows a first-order Hill equation. This behavior has classically been explained by steroid binding to receptor being the rate-limiting step. However, this predicts a constant potency of gene induction (EC 50 ) for a given receptor-steroid complex, which is challenged by the findings that various cofactors/reagents can alter this parameter in a gene-specific manner. These properties put strong constraints on the mechanisms of gene induction and raise two questions: How can a first-order Hill dose-response curve (FHDC) arise from a multistep reaction sequence, and how do cofactors modify potency? Here we introduce a theoretical framework in which a sequence of steps yields an FHDC for the final product as a function of the initial agonist concentration. An exact determination of all constants is not required to describe the final FHDC. The theory predicts mechanisms for cofactor/reagent effects on gene-induction potency and maximal activity and it assigns a relative order to cofactors in the sequence of steps. The theory is supported by several observations from glucocorticoid receptor-mediated gene induction. It identifies the mechanism and matches the measured dose-response curves for different concentrations of the combination of cofactor Ubc9 and receptor. It also predicts that an FHDC cannot involve the DNA binding of preformed receptor dimers, which is validated experimentally. The theory is general and can be applied to any biochemical reaction that shows an FHDC.
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dose-response | Michaelis-Menten | gene expression | steroid receptors | glucocorticoids | pharmacology I n ligand-mediated gene induction, the amount of gene expressed depends on the amount of ligand present. Thus, the specific shape and properties of the dose-response curve of gene induction, which is of crucial importance for development, differentiation, and homeostasis in many biological systems, provide a quantitative means for probing the gene-induction process. In many cases, the dose-response curve in gene induction obeys a sigmoidal curve, but not all sigmoidal curves have the same shape. For example, a dose-response curve obeying a first-order Hill equation or function (Hill coefficient equal to 1) goes from 10 to 90% of maximum activity over an 81-fold change in ligand concentration, whereas only a 9-fold change is required in a secondorder Hill function, which thus has a different shape (Fig. S1 ). (A first-order Hill function is sometimes called a Michaelis-Menten function.) Depending upon the shape of the dose-response curve, the responsiveness of gene induction to the same variation in ligand concentration will differ greatly. In addition to the shape, the position or potency [i.e., concentration required for 50% of maximal response (EC 50 )] and maximum activity (A max ) of the dose-response curve are required to specify the amount of gene expressed for a given amount of ligand. Despite the vital role that the dose-response curve plays in biological systems, the mechanisms that determine its shape and position remain poorly understood. Therefore, a better understanding of the control and shape of the dose-response curve may provide insights into the gene-induction process.
Steroid-mediated gene induction provides an excellent system for investigating basic questions about gene induction and doseresponse curves. The current model is that steroids enter the cell by passive diffusion and bind to intracellular receptors that can be predominantly cytoplasmic, as for glucocorticoid receptors (GRs), or nuclear, as for estrogen receptors. After a poorly understood step called activation, the receptor-steroid complex binds as a dimer with high affinity to biologically active DNA sequences [called hormone response elements (HREs)] to recruit additional transcriptional cofactors and modify the rates of transcription of nearby genes by the RNA polymerase complex. Glucocorticoids are an important class of steroids because they affect almost every cell and tissue in the body and are used to treat a variety of conditions, including asthma, autoimmune diseases, and cancer (1) . In most experiments, the observed dose-response curves closely match a first-order Hill function. This is the dose response for the actual amount of protein product measured, not the receptor occupancy or an initial reaction rate. The addition of various cofactors can shift the EC 50 and A max yet preserve the shape of the dose-response curve (2) (3) (4) . The fact that the multiple steps between ligand-receptor binding and translation to protein can yield a first-order Hill dose-response curve (FHDC) that can change position is remarkable. Here we develop a theoretical framework for a ligand-regulated gene-induction process that predicts the shape, position, and maximum activity of these dose-response curves. The theory is based on modeling the geneinduction process as an arbitrarily long sequence of complexforming steps or reactions. A set of stringent but biologically plausible constraints that yield an FHDC arises from the theory. The theory is mathematically tractable in that it manages the parameter explosion of mathematical modeling by generating formulas for the FHDC with a small number of parameters that can be applied quantitatively to data. Although here it is applied specifically to glucocorticoid-induced gene expression, our paradigm is applicable to any general biochemical pathways that exhibit FHDCs.
Model
Obtaining FHDCs. The basic principles of our theory can be demonstrated in some simple examples. In steroid-receptorregulated gene induction, the ligand binds to an intracellular receptor. The receptor-ligand complex then associates with DNA to initiate a series of transcriptional and translational processes (see Fig. S2 for an example of a reaction sequence). The classic explanation for an FHDC is that receptor-ligand binding is the rate-limiting step (5) . For example, consider the reaction Rþ S↔RS, for a receptor R and a ligand S. If the reaction obeys mass-action kinetics, then in equilibrium the concentrations obey ½RS ¼ q½R½S, where q is the affinity or association constant and square brackets indicate concentration. By mass conservation, ½R þ ½RS ¼ R T , where R T is the total receptor concentration. Solving the concentration and conservation equations gives the classic FHDC relationship between the complex and the freeligand concentration,
where A max = R T and EC 50 = 1/q are both constants. If this receptor-ligand reaction is the rate-limiting step for gene induction, then the concentration of gene product can be assumed to be proportional to [RS] . However, experiments show that EC 50 and A max are not constant and can be changed by cofactors that act downstream of ligand-receptor binding (6) , thereby ruling out the classic explanation. Thus, we are left with two questions: How can an FHDC arise for multiple reaction steps, and how can A max and EC 50 be controlled by cofactors?
In the gene-induction process, the receptor-steroid complex undergoes an activation step (or steps) culminating in binding to DNA, which is followed by multiple other steps such as the binding of transcription factors and the recruitment of polymerase (Fig. S2) . These steps are envisaged as the building of larger and larger complexes (7). However, considering just two steps of such a sequence, for example, R þ S↔RS and RS þ D↔RSD (where D represents DNA), does not generally lead to an FHDC for the product [RSD] ). In this case, the two reactions R þ S↔RS and RS þ D↔RSD "decouple" and can be solved independently to yield Eq. 1 (with q = q 1 ) and
Combining the two equations then yields the FHDC
This property that the combination of two FHDCs results in another FHDC has been used previously (8, 9) . Here we show how this property, which arises because the FHDC is in the family of Möbius or fractional linear transforms and forms a group under function composition (SI Section 2), can be generalized to any set of complex-forming biochemical reactions and allows us to derive a formula for the dose-response curve for an arbitrarily long reaction sequence. We consider the biological conditions under which this can occur below. We also note that the expressions for
they can now be altered by factors downstream of receptorsteroid binding. This FHDC property can also be exploited in diverse ways, which is seen by adding a third reaction, RSD þ U⇔RSDU, where U is a cofactor such as Ubc9. The concentration equations for the three reactions are now ½RS ¼ q 1 ½R½S, ½RSD ¼ q 2 ½RS½D, and ½RSDU ¼ q 3 ½RSD½U, and the mass-conservation equations are (6, 10, 11) . Considerable experimental evidence has been advanced in support of transient binding (dubbed "hit and run") of GR to endogenous genes (12, 13). We show below how these concepts can be applied to a sequence of complex-forming reactions in a general gene-induction process.
General Theory. Consider a sequence of n binary reactions of the form Y i − 1 þ X i ↔Y i , where i = 1, 2,. . ., n, is an index for a reaction. Let Y 0 be the ligand, X 1 be the receptor, and Y 1 be the receptor-ligand complex. We call the subsequent X variables activators or cofactors and the Y variables products. The reactions need not be reversible; they only should reach a stationary or a steady state. Hence, any number of the reactions could be irreversible with decay, that is, 
where ε i is 1 or 0, indicating the presence or absence of [Y i ] in the equations.
Step cls is the general definition of the CLS (introduced above). In this step, the concentration of factor X cls is small compared with the concentration of the other activators. Hence, all terms appear in its conservation condition. For all steps after the CLS, the free concentration of any activator is equal to its total concentration. Hence, the location of the CLS can move by adding or removing varying amounts of activators. The CLS also need not exist for all situations. For reactions obeying the steady-state concentration equations and mass conservation (Eq. 3), the equations can be solved exactly using the group property of the fractional-linear transformation (SI Section 2) to obtain a formula for the dose-response curve,
where A is the activity of the gene and Γ ¼ ∑ Table 1 . These factors specify the action of the cofactor at step i and take different forms depending on location with respect to the CLS. As is evident from comparison with Eq. 1, A max ¼ ΓV Eq. 4 depends on 4n − cls þ 1 free parameters, namely the a, ε, q, and X T parameters, and the choice of these parameters specifies a model for the data. In general, all of these parameters and even the number of steps will be unknown. However, the formula is useful because the number of effective parameters necessary to specify a model can be reduced because any sequence of steps collapses or "telescopes" into a single firstorder Hill function with an effective A max and EC 50 . The result is that there are now only three effective "steps" to consider (before, at, or after the CLS), which reduces the possible parametric models that can explain a given experiment to a small number involving a finite set of cofactors. One also does not need to know a priori whether there even is a CLS. By applying the different possible models to the data, the existence of a CLS can be inferred. The CLS could be located experimentally by finding the cofactor that affects the dose-response curve in the appropriate manner for the CLS, as predicted by the theory. The reaction sequence also has a "modular" structure in that reactions, or a sequence of reactions, can be inserted, deleted, or combined without affecting the FHDC. Arbitrarily complex reaction sequences that maintain first-order Hill form can be constructed in this way. Thus, different genes could mix and match different pieces of the reaction sequence and all have FHDCs but with different A max and EC 50 .
Incorporation of Inhibitors. We have only considered activators so far. However, it is known that inhibitors, which act by reducing the concentration or efficacy of activators or products, can affect gene induction (10, 11). The reaction scheme for an inhibitor I i acting at step i that preserves FHDC form is where the parameters obey 0 ≤ α ≤ 1, 0 ≤ γ ≤ 1, and 0 ≤ β. The case of α ¼ 0 is called competitive inhibition, γ ¼ 0 is called uncompetitive inhibition, α ¼ γ is called noncompetitive inhibition, β ¼ 0 is called linear inhibition, and β > 0 is called partial inhibition. Although I is called an inhibitor, its actions need not be inhibitory or repressive on the final activity. For example, if β > 1, I can be activating because it diverts the output from a lower-yield product to a higher-yield one. The dependence of Y i and Y Ã i on Y i−1 is derived in SI Section 3 (following refs. 10 and 11) by solving the concentration and mass-conservation equations to obtain formulas for factors v i and w i , which specify the actions of the inhibitor on the activator at step i and are listed in Table 1 . Inhibitory steps can be inserted anywhere in the reaction sequence before the CLS, but only competitive inhibitors can occur after the CLS.
Results
Application to Steroid-Mediated Gene Induction. To demonstrate the utility of our theory, we have applied it to steroid-receptor- Table 1 . Values for v i and w i for activator and inhibitor at position i before, at, or after CLS
Position
Activator Activator with inhibitor
where an FHDC has been observed experimentally. When a cofactor is added, A max and EC 50 of the dose-response curve can increase, decrease, or not change (4) . Mechanisms for these various combinations can be predicted using Eq. 4 expressed in a form so that the inhibitor [I i ] or activator X T i concentrations are visible (SI Section 4). Leaving out the combination of both not changing, we have experimentally observed seven of the eight remaining scenarios that are listed in Table 2 along with the predicted mechanisms. Although these suggested mechanisms are not unique (some of the scenarios are consistent with multiple mechanisms; see also SI Section 5), the predictions are consistent with previous results (6), as described below.
Quantitative Predictions for Ubc9. To uniquely identify a mechanism, the set of parameters specifying a model must be estimated directly from the data. We show this for the unusual capacity of the comodulator Ubc9 to cause different responses in transiently transfected cells depending upon the concentration of steroid receptor (6, 14, 15) . (Experimental methods are in SI Section 8.) To generate numerous data points for an exacting test of our model, we used six different steroid (Dex) concentrations to define the dose-response curves for four levels of GR with three amounts of Ubc9 (Fig. 1) . With low levels of GR, Ubc9 increases the A max of luciferase activity while perturbing EC 50 marginally. At higher receptor concentrations, there is a less proportional increase in A max and a greater decrease in EC 50 . In all cases, an FHDC is always seen. In addition to extracting parameters to specify a mechanism, applying Eq. 4 to the data of Fig. 1 also gives an independent test of the model. We first must reexpress Eq. 4 so that three factor concentrations (steroid, receptor, and Ubc9) are visible in the formula (SI Section 4). However, whereas the steroid and receptor are assumed to appear in the first reaction, it is not known where Ubc9 appears. Hence, we must consider the possibility that it is before, at, or after a possible CLS. Recall that the CLS represents the step for which the cofactor has the smallest concentration compared with the other cofactors. The case of no CLS has the same formula as Ubc9 appearing before the CLS. The applicable formula has the form (SI Section 4)
where A represents the luciferase activity, U T denotes the total Ubc9 concentration, R T equals the total steroid-receptor concentration, [S] is the free-steroid concentration, which we assume is approximated by the total steroid concentration, and the C parameters (given in Table S1 ) differ depending on where Ubc9 acts. Table S1 shows that if Ubc9 acts at the CLS (i.e., it is the concentration-limiting step), then it cannot affect EC 50 , so we can rule that possibility out. We fit Eq. 5 to the complete dataset of multiple doses of S, R, and Ubc9. Fig. 1 shows that the model captures the data fairly well, thereby reinforcing the validity of the model. The fitting algorithm and estimated parameter values are in SI Section 6. Given the parameters, we can predict where Ubc9 acts. The model fit finds the ratio of C 1 /C 2 U T ∼ 1. If Ubc9 acts before the CLS, then this ratio implies that the endogenous to exogenously applied Ubc9 ratio in the cell is near 1 (U T = 0 implies there is no exogeneous Ubc9). However, quantitative reverse transcription-PCR measurements give a ratio of ∼100, which rules out this possibility. Thus, we conclude that Ubc9 is an activator that acts after the CLS, as was hypothesized previously (14, 15).
GR Monomer Versus Dimer Binding to DNA. In the prevailing model of steroid hormone action, preformed dimers of receptor-steroid complex bind to the biologically active HREs of target genes (7, 16 ). However, our theory predicts that such a cooperative step will destroy the FHDC. Thus, in those cases where a steroid produces an FHDC, our theory predicts that GR dimerization cannot be a necessary step for gene induction and vice versa (see SI Section 7 for a theoretical justification). In support of our theory, recent NMR studies show conformational changes in DNA-bound dimers occurring after the DNA binding of monomeric receptor (18). Furthermore, experiments with both steroid receptors (19-22) and helix-loop-helix zipper transcription factors (23, 24) strongly suggest that the majority of receptor binding to HREs occurs not by preformed dimers but by monomers that then form dimers on the DNA. To further examine this issue, we performed new experiments. We looked at the activity of several known dimerizationdefective mutants (GR A477T, R479D, and D481R) (21, 25), plus a new double mutant (GR A477T/I646A) with a mutation in the dimerization domains of both the DNA-binding domain and ligand-binding domain (26). Each mutant is expressed at equivalent levels (Fig. S3) , is active, and yields an FHDC (Fig. 2A) . We then find that Ubc9 increases the A max (while decreasing the fold induction) and decreases the EC 50 of each mutant, similar to that seen with the wild-type GR (Fig. 2B and Fig. S4 ). We therefore conclude that defects in GR dimerization do not prevent GR transactivation or the modulatory activity of Ubc9, as predicted by our theory.
Discussion
We have described a theoretical framework for ligand-mediated gene induction that was applied specifically to glucocorticoid hormone action but is applicable to any biochemical pathway that exhibits an FHDC. The theory produces a formula for the FHDC describing how the A max and the EC 50 can change and yields mechanistic insights that are not obtainable with the common practice of examining just A max ( Table 1 ). The theory shows that any number of first-order steps of arbitrary complexity telescope into a single expression, with an effective A max and EC 50 , consisting of just three steps that are before, at, or after a CLS. The steps involved need not be reversible as long as they reach steady state or equilibrium. An FHDC-preserving reaction sequence has a modular structure in that reactions can be inserted, deleted, or combined. In fact, different genes could possibly mix and match different pieces of the reaction sequence and all have FHDCs but with different A max and EC 50 . Our theory yields valuable information and testable hypotheses even when the precise steps of action are unknown. Despite minimal initial experimental constraints, the theory accounted for all of the different combinations of changing A max and EC 50 that have been observed experimentally. The validity of the theory is further supported by its successes in explaining how steps well downstream of ligand binding can alter the A max and EC 50 (6, 27) . The theory defines a CLS, which is an equilibrium/ steady-state analog of the rate-limiting step. One property of the CLS is that products from all steps after it can be summed directly and still preserve an FHDC. As shown in Table 1 , the theory makes specific predictions of both biochemical mechanism of cofactor action and site of action relative to the CLS. For example, Table 1 predicts that the changes in A max and EC 50 of gene induction by high concentrations of GR upon addition of Ubc9 result from Ubc9 functioning as an activator before or after the CLS. Other experiments then restricted the possible mechanisms to Ubc9 acting as an activator downstream of the CLS, providing confirmation for our previous hypothesis of Ubc9 acting downstream of GR and a rate-limiting step (14). One also does not need to know a priori whether there is a CLS. The CLS could be located by finding a cofactor that affects the doseresponse curve, as predicted by the theory.
A stringent test for application of our theory is the invariance of an 81-fold change between 0.1 and 0.9 of maximal induction under all conditions. More generally, the fold change between a fraction p and 1 − p of maximal induction is (1 − p) 2 /p 2 . This does not hold for a general complex-forming sequence of reactions. Additionally, we note that the first-order Hill function is the only Hill function that preserves its form when substituted into itself (i.e., forms a group under function composition). Higher-order Hill functions will be driven to a "switch-like" activation curve with the inclusion of more such steps, whereas lower-order ones will be driven to a flat activation curve (Fig.  S1) . Thus, any reaction scheme that is not described by our theory would be unlikely to produce the 81-fold change.
Another critical test of the model came with its prediction that appreciable DNA binding of preformed receptor dimers, which is widely believed to occur, cannot be necessary for steroidinduced gene expression in all situations. This does not mean that steroid receptors never bind to HREs as preformed dimers. Indeed, examples of non-FHDCs could indicate steps like receptor dimers or other cooperative behaviors that break the FHDC. Instead, our model says that the observation of an FHDC uniquely restricts the mechanism for receptor regulation of the observed gene to one that does not require preformed dimers. We show that three GR mutants with documented low to negligible binding as dimers to DNA, plus a combination double mutant that would be expected to be even less capable of dimer formation, are all still active with A max and EC 50 values that are modulated by exogenous Ubc9, as described by the model (Fig. 2 and Figs. S3 and S4 ). These and previous results of others suggest that the initial binding to biologically active DNA sequences involves predominantly GR monomers, as opposed to preexisting dimers, when the dose-response curve obeys first-order Hill form.
Although the studies of the current report are all with the transiently transfected reporter GREtkLUC, we have observed FHDCs with several endogenous genes for GR-mediated induction and repression (27-30). However, dose-response curves with other endogenous genes and/or other conditions (28) indicate nonFHDCs, which could serve as a valuable screen for systems where additional factors/processes contribute to the overall control of gene expression in a manner that violates the conditions of the theory. Our theory also does not include the effects of biomolecular fluctuations due to small numbers of molecules. We 12, 13, 42) . Indeed, the rapid binding of steroid receptors is a consequence of FHDC and a prediction of our theoretical framework. 
which can be solved to obtain We first define new parameters, so we can rewrite Eq. S1.1 as
Define S p to be the amount of steroid that induces pY max , where p is a fraction and the maximal induction Y max is the solution of the critical-point equation aY
Substituting in [RSD] = pY max and c ¼ − aY 2 max þ bY max in Eq. S1.3 yields
The p to 1 − p fold change is then
Hence, the 10-90% fold change is given by 81(1 − 1.1z)/(1 − 1.9z), where z ¼ aY max =b and 0 ≤ z ≤ 0:5. The fold change is an increasing function of Y max and is not FHDC except when Y max is small, which is also where the quadratic term in Eq. S1.1 is small. This proof can be generalized to an arbitrary number of reactions. Dropping the quadratic term in Eq. S1. 
, which does not yield an FHDC.
Section 2. Derivation of the FHDC for the General Theory
For reactions obeying the concentration equations and conservation Eq. 3 in the main text, the equations can be solved in pairs so that each product is a first-order Hill function of the previous product, that is,
where v i and w i have explicit formulas listed in Table 1 in the main text and have different forms depending on location with respect to the concentration-limiting step (CLS). We can then compose these first-order Hill functions (i.e., substitute one function into another) to obtain any downstream product as a function of any upstream product. The calculation is simplified by the observation that the firstorder Hill function is in the family of fractional linear or Möbius transformations and forms a group under function composition, which can be represented by matrix multiplication of 2-by-2 matrices. Consider a set of fractional linear functions written in the form of Eq. S2.1, and we want to compute the composition of two functions ½Y 2 ð½Y 1 ð½Y 0 ÞÞ to obtain ½Y 2 as a function of ½Y 0 . The coefficients of each function are entered as elements of a matrix ½Y i ⇒ v i 0 w i 1 . Then ½Y 2 ð½Y 1 ð½Y 0 ÞÞ is given by a multiplication of the matrices representing ½Y 2 and ½Y 1 , that is,
, from which the composed function can be reconstructed to obtain 
where Γ ¼ ∑ n k¼cls a k − cls V k clsþ1 . Section 3. Inhibition Consider the general reaction scheme for an inhibitor I i acting on an activator X i .
The mass-conservation law is
and the concentration equations are [1, 2] 
Substituting the individual equilibrium conditions back into the mass-conservation equation gives
, which can be solved for ½X i and then substituted back into the concentration equation for ½Y * i to yield
The two products ½Y * i and ½Y ′ i can then be summed via
If the inhibitor acts at or after the CLS of a reaction sequence, then the equations are modified. If the inhibitor acts at the CLS (i ¼ cls), then the mass-conservation equation becomes
If the inhibitor acts after the CLS, then the mass-conservation equation
, which implies only linear competitive inhibition can occur leading to Eq. S3.1 with α i ¼ 0, β i ¼ 0, and ε i ¼ 0. ½Y i can be put into the standard form of
½IÞ and w i ¼ 0 [i.e., same as (i) with
These results are summarized in Table 1 of the main text.
Section 4. Isolating Total Concentration of Cofactors in the Product Function
Here we show how the model form can be explicitly constructed for an arbitrary number of factors to be visible with effective parameters, which can then be compared to data. We show examples for two activators and for an inhibitor and an activator. From main-text Eq. 4, the general form for the final product is
, and v i and w i differ depending on position with respect to the CLS and type of factor (see Table 1 of the main text). Now suppose we have two activators and the first activator acts before the CLS at step i and the second acts at step j, which can be before, at, or after the CLS. We want to make the total concentrations X T i and X T j visible in the final product. We do so by isolating factors of v i and v j , and w cls ¼ q cls ∑ n k¼cls ε k ∏ k j¼clsþ1 v j . For the case i < j < cls, we can rewrite V cls
Thus, we can write
where 
. The results for the three cases are summarized in Table S1 . Now, consider the action of an activator and inhibitor at step i. In this case, the activator and inhibitor could both act at the same step or at different steps. First consider the case where i < cls. Again we decompose
to obtain the final product
into an endogenous and an exogenous part and then redefine the parameters as before. For the case i ¼ cls,
so that the D parameters are the same as for i < cls except
, and α i ¼ 0. The parameters are summarized in Table S1 . 
where the D parameters are listed in Table S1 and we have dropped the index subscript. We can consider how the activator X T or inhibitor ½I affects A max and EC 50 individually. The derivative of A max and EC 50 with respect to X T while fixing ½I ¼ 0 is
and the derivative of A max and EC 50 with respect to ½I while fixing X T ¼ 1 is
where
Although the parameters are composed of an unknown number of constants associated with the reactions, they can be estimated directly from the data as shown in SI Section 6 below. If the derivatives are positive, negative, or zero, then the respective quantity increases, decreases, or does not change. The values of the parameters will then determine the sign of the derivative. However, some predictions about the mechanisms and location of a cofactor with respect to the CLS can be made based on how A max and EC 50 move with the addition of the cofactor.
Eq. S5.1 shows that A max will increase with the addition of an Table S1 , we see that the magnitude of D 1 is controlled by products downstream of the activator and D 0 by those upstream. Thus, A max can decrease if the downstream reactions contribute less to the final product than upstream reactions (i.e., are slower) and vice versa. A max does not change if the two contributions balance each other, although this would require fine-tuning and thus be unlikely. In summary, an activator will generally increase A max . However, if there are slow reactions downstream of the activator, then A max can decrease. The interesting point is that there are situations where A max can decrease with the addition of an activator.
For an activator, Eq. S5.2 shows that EC 50 always decreases unless From Table S1 we see that D 5 = 0 if an activator acts at the CLS. The inequality D 5 < < D 2 could be satisfied if there are reactions following the activator that are slower. Hence, EC 50 generally decreases if an activator acts before or after the CLS but could possibly change very slowly and appear not to change. If the activator acts at the CLS then EC 50 will not change. Hence, an activator cannot increase EC 50 .
From Eqs. S5.3 and S5. 4 , we see that determining the action of an inhibitor is less straightforward. However, we can still make some general statements if we consider the actions of different types of inhibition (i.e., competitive, uncompetitive, noncompetitive, linear, partial) acting before, at, or after the CLS. From Eq. S5. 4 , we see that EC 50 decreases for uncompetitive inhibition (γ ¼ 0) and increases for competitive inhibition (α ¼ 0). EC 50 does not change for a partial noncompetitive inhibitor acting before the CLS (D 0 = 0, D 4 ¼ 1, α ¼ γ, β ¼ 1). These behaviors can still hold if the inhibition is mixed but close to these special cases. Thus, for inhibition, it is possible for A max and EC 50 to both move in any direction.
From these conditions, we can make some predictions of the actions of cofactors listed in Table 2 of the main text. We note that these predicted mechanisms are not exclusive. For specificity and brevity, we assumed the simplest possibility in Table 2 . More precise predictions can only be made if the D parameters are estimated from the data. S2 . Examples of some possible steps in steroid hormone action that can result in an FHDC. For simplicity, not all currently proposed steps are shown and no attempt has been made to identify which steps are reversible/cycling or irreversible, because all are allowed as long as the reactions reach a stationary or steady state. The steroid (S) binds to receptor (R), which then binds to DNA. The bound RS-DNA complex must have a smaller average concentration than the RS complex, or interact transiently. If a cofactor A binds to the RS-DNA complex, then it must also act transiently or its average concentration must be small compared with the concentration of the bound RS-DNA complex. The bound RS-DNA-A complex can transition directly into another state G. State G can be induced in a "hit-and-run" reaction by a cofactor B to transition into a state H. Some point in the reaction sequence could contain a CLS step. After the CLS, the concentrations of the free cofactors are unperturbed by reactions. Each of the steps after the CLS can be combined to form the final mRNA product, which is then translated into protein. 
